HESTERBIO
Hester Biosciences
Each stock's 10,000-path forecast, rendered as light.
Hester Biosciences (HESTERBIO) Stock Analysis & Case Study
Is HESTERBIO a good buy? The data-driven verdict.
Hester Biosciences (HESTERBIO) trades at ₹2,149,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Hester Biosciences (HESTERBIO) tread carefully, a Downstox Snapshot Score of 41/100, weighing premium at 34.1× earnings, ROE of 15.9%, a 31% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
HESTERBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is HESTERBIO overvalued? HESTERBIO P/E vs its sector
HESTERBIO's P/E of 34.1× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.51% dividend yield is below the peer median of 1.65%.
HESTERBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of HESTERBIO history (-11%/yr drift, 44%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| HESTERBIO 2027 | ₹964 | ₹1,681 | ₹2,905 | -19% |
| HESTERBIO 2028 | ₹613 | ₹1,348 | ₹3,040 | -35% |
| HESTERBIO 2029 | ₹420 | ₹1,098 | ₹2,965 | -47% |
| HESTERBIO 2030 | ₹293 | ₹890 | ₹2,818 | -57% |
| HESTERBIO 2031 | ₹209 | ₹722 | ₹2,626 | -65% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability HESTERBIO goes up, or doubles?
The bull case for HESTERBIO
- A healthy 15.9% return on equity.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,965.
The bear case & risks
- At 34.1× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- The probability model is cautious 12 months out, only a 31% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹420.
HESTERBIO volatility & expected range, how bumpy is the ride?
Over the last 2.0 years HESTERBIO compounded at -11%/year with annualized volatility of 44%. That volatility implies a 1-year 80% range of ₹964–₹2,905, the honest backbone behind any single price target.
HESTERBIO price forecast, the full 60-month probability fan
HESTERBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds HESTERBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the HESTERBIO price target & forecast page.
HESTERBIO Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. HESTERBIO scores 4/9,mixed financial health.
HESTERBIO MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy HESTERBIO with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 35.0% | 2.9× |
| Zerodha | 50.0% | 2.0× |
| Dhan | 50.0% | 2.0× |
Compare every broker on the HESTERBIO MTF page.
HESTERBIO vs peers,sector comparison
About Hester Biosciences: sector, index & market-cap context
Hester Biosciences (HESTERBIO) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹1,828 Cr. See more Nifty 500 stocks.
How the HESTERBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Hester Biosciences's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
HESTERBIO analysis, FAQs
Is Hester Biosciences (HESTERBIO) a good buy?
On the numbers, Hester Biosciences (HESTERBIO) tread carefully, a Downstox Snapshot Score of 41/100, weighing premium at 34.1× earnings, ROE of 15.9%, a 31% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is HESTERBIO overvalued or undervalued?
HESTERBIO trades at 34.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the HESTERBIO share price target for 2031?
HESTERBIO's probability-weighted 2031 median target is ₹722, with an 80% range of ₹209–₹2,626 (10,000-path Monte-Carlo).
What is the probability HESTERBIO doubles in 5 years?
The modelled probability of HESTERBIO reaching ₹4,153 (2×) within 5 years is 4%.
What is the bull case for HESTERBIO?
A healthy 15.9% return on equity.
What are the risks in HESTERBIO?
At 34.1× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. The probability model is cautious 12 months out, only a 31% chance of finishing above today's price.